1. Home
  2. RVMD vs LII Comparison

RVMD vs LII Comparison

Compare RVMD & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Revolution Medicines Inc.

RVMD

Revolution Medicines Inc.

HOLD

Current Price

$149.27

Market Cap

19.2B

Sector

Health Care

ML Signal

HOLD

Logo Lennox International Inc.

LII

Lennox International Inc.

HOLD

Current Price

$483.09

Market Cap

15.8B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVMD
LII
Founded
2014
1895
Country
United States
United States
Employees
883
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
19.2B
15.8B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
RVMD
LII
Price
$149.27
$483.09
Analyst Decision
Strong Buy
Hold
Analyst Count
19
13
Target Price
$135.05
$566.58
AVG Volume (30 Days)
2.4M
380.4K
Earning Date
05-06-2026
04-29-2026
Dividend Yield
N/A
1.00%
EPS Growth
N/A
1.11
EPS
N/A
22.79
Revenue
N/A
$5,195,300,000.00
Revenue This Year
N/A
$6.90
Revenue Next Year
$411.49
$5.73
P/E Ratio
N/A
$22.84
Revenue Growth
N/A
N/A
52 Week Low
$34.00
$434.06
52 Week High
$148.00
$689.44

Technical Indicators

Market Signals
Indicator
RVMD
LII
Relative Strength Index (RSI) 86.84 48.54
Support Level $93.39 $481.66
Resistance Level N/A $498.78
Average True Range (ATR) 4.31 18.54
MACD 6.04 7.48
Stochastic Oscillator 96.35 54.54

Price Performance

Historical Comparison
RVMD
LII

About RVMD Revolution Medicines Inc.

Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

About LII Lennox International Inc.

Lennox International manufacturers and distributes heating, ventilating, air conditioning, and refrigeration products for the North American replacement (75% of sales) and new construction (25% of sales) markets. Residential HVAC (home comfort solutions) accounted for 67% of sales and commercial HVAC (building climate solutions) accounted for the remaining 33% of sales. To be clear, Lennox's commercial exposure is what its peers refer to as "residential and light commercial," lacks the scale and complexity of what is referred to as an "applied" solution. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand.

Share on Social Networks: